Stock Watch: Rare Diseases Beget Rare Profitability
Profits Elude Alnylam Despite Three Product Launches
Executive Summary
Do rare disease drugs with tiny patient populations lie outside the profitability continuum that runs from small-molecule primary care products to specialist biologics?